Mapping Drug Resistance Genes in Plasmodium Falciparum
绘制恶性疟原虫的耐药基因图谱
基本信息
- 批准号:7364133
- 负责人:
- 金额:$ 46.11万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-09-01 至 2011-01-31
- 项目状态:已结题
- 来源:
- 关键词:AllelesAntimalarialsArtemisininsCandidate Disease GeneChromosomes, Human, Pair 5ClassClinicClinicalCollaborationsDrug resistanceEffectivenessEvolutionFundingGene MutationGenesGenetic PolymorphismGenomeGenotypeLaboratoriesLocationMalariaMapsMeasuresMedicineMicrosatellite RepeatsMonitorMutationMyanmarNucleotidesNumbersParasitesPatientsPharmaceutical PreparationsPhenotypePlasmodium falciparumPoint MutationPublic HealthQuantitative Trait LociRecrudescencesResearchResistanceRunningSamplingScreening ResultSeriesThailandTransfectionTreatment EfficacyTreatment FailureWorkartemisinineclinically relevantcollegecomparativedayefficacy trialfollow-upimprovedin vivokillingsmortalityresearch studyresponsetool
项目摘要
Drug resistance is the major obstacle to control of malaria and the spread of resistance has increased
malaria mortality over recent decades. Identification of parasite genes that influence drug response would
improve our ability to monitor resistance spread, provide tools for better understanding the mode of action of
antimalarials, and allow rational redesign of existing drugs. In Thailand the problem is particularly severe with
high levels of resistance to all classes of antimalarials except for the artemisinin derivatives. In the initial
funding period of this project we measured response to eight drugs in 825 parasite isolates from a single
clinic on the Thailand-Burma border, and then genotyped 323 single-clone parasites using 426 di-nucleotide
microsatellite markers spaced at 50kb (~3cM) intervals throughout the genome. This work resulted in
identification of a number of candidate regions that show association with response to one or more drugs.
This renewal application capitalizes on these findings. We propose to (1) identify candidate genes and
alleles that influence drug response using comparative sequencing and fine-scale association mapping, (2)
use rapid transfection approaches to confirm which of the candidate genes identified are involved in
resistance, and (3) examine whether specific alleles in these genes can predict drug treatment failure using
clinical samples collected from patients in Thailand.
Relevance of this research to public health. Malaria kills over one million people each year. The mainstay
of malaria control is drug treatment, but treatment options are rapidly running out due to the evolution of
resistance. We aim to locate parasite genes underlying resistance. This will allow us to track the spread of
resistance, to better understand how antimalarial drugs work, and to redesign drugs to restore their
effectiveness.
抗药性是控制疟疾的主要障碍,抗药性的传播有所增加
近几十年来疟疾死亡率。鉴定影响药物反应的寄生虫基因将
提高我们监测耐药性传播的能力,提供工具,更好地了解
因此,我们必须考虑到现有的抗疟药物,并允许合理地重新设计现有的药物。在泰国,这个问题尤其严重,
对除青蒿素衍生物以外的所有类别的抗疟药物都有高度抗药性。在初始
在该项目的资助期间,我们测量了来自一个单一的825个寄生虫分离株对八种药物的反应。
泰国-缅甸边境的一家诊所,然后使用426个双核苷酸对323个单克隆寄生虫进行基因分型。
微卫星标记在整个基因组中以50 kb(~3cM)间隔分布。这项工作导致
识别显示与对一种或多种药物的响应相关的多个候选区域。
此更新应用程序利用了这些发现。我们建议(1)确定候选基因,
使用比较测序和精细尺度关联映射影响药物反应的等位基因,(2)
使用快速转染方法来确认哪些候选基因参与了
耐药性,以及(3)检查这些基因中的特定等位基因是否可以预测药物治疗失败,
从泰国患者身上采集的临床样本。
这项研究与公共卫生的相关性。疟疾每年夺去100多万人的生命。主体
控制疟疾的最有效手段是药物治疗,但由于疟疾的发展,
阻力我们的目标是找到寄生虫抵抗力的基因。这将使我们能够追踪
为了更好地了解抗疟药物的工作原理,并重新设计药物,以恢复其耐药性,
有效性
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tim J Anderson其他文献
Tim J Anderson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tim J Anderson', 18)}}的其他基金
Genomic consequences of schistosome hybridization
血吸虫杂交的基因组后果
- 批准号:
10346459 - 财政年份:2021
- 资助金额:
$ 46.11万 - 项目类别:
Genomic consequences of schistosome hybridization
血吸虫杂交的基因组后果
- 批准号:
10678916 - 财政年份:2021
- 资助金额:
$ 46.11万 - 项目类别:
Genetic analysis of cercarial release in schistosomes
血吸虫尾蚴释放的遗传分析
- 批准号:
10190794 - 财政年份:2017
- 资助金额:
$ 46.11万 - 项目类别:
Efficient Linkage Mapping Methods for Schistosoma mansoni
曼氏血吸虫的高效连锁作图方法
- 批准号:
8386269 - 财政年份:2012
- 资助金额:
$ 46.11万 - 项目类别:
Efficient Linkage Mapping Methods for Schistosoma mansoni
曼氏血吸虫的高效连锁作图方法
- 批准号:
8500172 - 财政年份:2012
- 资助金额:
$ 46.11万 - 项目类别:
Genetic Analysis of Host Specificity in Schistosoma mansoni
曼氏血吸虫宿主特异性的遗传分析
- 批准号:
8401136 - 财政年份:2011
- 资助金额:
$ 46.11万 - 项目类别:
Identification of Novel Plant-derived Antimalarial Compounds
新型植物源抗疟化合物的鉴定
- 批准号:
8298963 - 财政年份:2011
- 资助金额:
$ 46.11万 - 项目类别:
相似海外基金
Developing inhibitors of Plasmodium Acetyl CoA Synthetase as new multistage antimalarials
开发疟原虫乙酰辅酶A合成酶抑制剂作为新型多级抗疟药
- 批准号:
MR/X030202/1 - 财政年份:2023
- 资助金额:
$ 46.11万 - 项目类别:
Research Grant
Novel Dual-Stage Antimalarials: Machine learning prediction, validation and evolution
新型双阶段抗疟药:机器学习预测、验证和进化
- 批准号:
10742205 - 财政年份:2023
- 资助金额:
$ 46.11万 - 项目类别:
Natural Product Inspired Novel Antimalarials with Radical Cure Potential
受天然产物启发的具有根治潜力的新型抗疟药
- 批准号:
10635649 - 财政年份:2023
- 资助金额:
$ 46.11万 - 项目类别:
Novel Synergistic Antimalarials with Resistance Reversal Function
具有耐药逆转功能的新型协同抗疟药
- 批准号:
10534667 - 财政年份:2022
- 资助金额:
$ 46.11万 - 项目类别:
Plasmodium Protein Kinase Focused Antimalarials Discovery
疟原虫蛋白激酶聚焦抗疟药的发现
- 批准号:
10533634 - 财政年份:2022
- 资助金额:
$ 46.11万 - 项目类别:
DMPK Optimisation of B-hydroxyethylamine Antimalarials
B-羟乙胺抗疟药的 DMPK 优化
- 批准号:
2749037 - 财政年份:2022
- 资助金额:
$ 46.11万 - 项目类别:
Studentship
Development of new lead antimalarials targeting parasite coenzyme A biosynthesis and utilisation.
开发针对寄生虫辅酶 A 生物合成和利用的新型先导抗疟药。
- 批准号:
468862 - 财政年份:2022
- 资助金额:
$ 46.11万 - 项目类别:
Operating Grants
Repurposing antimalarials for the treatment of NTM infections
重新利用抗疟药治疗 NTM 感染
- 批准号:
10646331 - 财政年份:2022
- 资助金额:
$ 46.11万 - 项目类别:
Novel Synergistic Antimalarials with Resistance Reversal Function
具有耐药逆转功能的新型协同抗疟药
- 批准号:
10368441 - 财政年份:2022
- 资助金额:
$ 46.11万 - 项目类别:
Plasmodium Protein Kinase Focused Antimalarials Discovery
疟原虫蛋白激酶聚焦抗疟药的发现
- 批准号:
10663334 - 财政年份:2022
- 资助金额:
$ 46.11万 - 项目类别: